Lonza Group AG Lonza Group AG

Lonza Group AG

LONN

주식 순위 #449
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
주가
$763.31
시가총액
$53.31B
변동 (1일)
0.87%
변동 (1년)
8.49%
국가
CH
거래 Lonza Group AG (LONN)

카테고리

Healthcare
Lonza Group AG (LONN)의 수익
2026 기준 수익 TTM: 0
Lonza Group AG의 최신 재무 보고서에 따르면 회사의 현재 수익은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 수익 0과 동일입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Lonza Group AG의 수익 기록 (2004 ~ 2026)
연말 수익
연도 수익 변화
2025 $1.39B 77.01%
2024 $783.78M -16.56%
2023 $939.36M -40.02%
2022 $1.57B 87.88%
2021 $833.60M -4.61%
2020 $873.87M 18.24%
2019 $739.09M -9.57%
2018 $817.28M 49.73%
2017 $545.84M 48.94%
2016 $366.48M 7.42%
2015 $341.15M 21.46%
2014 $280.87M 138.68%
2013 $117.67M -48.71%
2012 $229.45M 23.16%
2011 $186.30M -47.24%
2010 $353.12M 96.17%
2009 $180.00M -59.52%
2008 $444.71M 39.23%
2007 $319.41M 55.15%
2006 $205.88M 36.16%
2005 $151.21M -3.96%
2004 $157.45M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -
US
$-3.09B -
US
$-4.02B -
AU
$1.95B -
NL
$3.01B -
BE